XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Operating Segment Information (Tables)
9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Schedule of segments
The major product groups of each reportable operating segment are as follows:
Segment
Product Group
Titanium Dioxide
titanium dioxide
Performance Additives
functional additives, color pigments, timber treatment and water treatment chemicals
Schedule of segments The revenues and adjusted EBITDA for each of the two reportable operating segments are as follows:
Three months ended
September 30,
Nine months ended
September 30,
2020201920202019
Revenues:
Titanium Dioxide$343 $396 $1,083 $1,260 
Performance Additives131 130 379 406 
Total$474 $526 $1,462 $1,666 
Adjusted EBITDA(1)
Titanium Dioxide$21 $51 $102 $167 
Performance Additives5 13 40 44 
26 64 142 211 
Corporate and other(9)(14)(31)(40)
Total17 50 111 171 
Reconciliation of adjusted EBITDA to net (loss) income:
Interest expense(18)(13)(46)(40)
Interest income3 3 9 9 
Income tax expense(3)(8)(3)— 
Depreciation and amortization(29)(27)(85)(82)
Net income attributable to noncontrolling interests3 2 6 4 
Other adjustments:
Business acquisition and integration expenses— (2)(1)(3)
Gain (loss) on disposition of business/assets6 (1)4 (1)
Certain legal expenses/settlements— (2)(3)(3)
Amortization of pension and postretirement actuarial losses(3)(3)(10)(11)
Net plant incident costs(2)(4)(5)(17)
Restructuring, impairment and plant closing and transition costs(13)(12)(25)(24)
Net (loss) income$(39)$(17)$(48)$3 

(1)Adjusted EBITDA is defined as net income/loss of Venator before interest expense, interest income, income tax expense/benefit, depreciation and amortization and net income attributable to noncontrolling interests, as well as eliminating the following adjustments: (a) business acquisition and integration expenses/adjustments; (b) loss/gain on disposition of business/assets; (c) certain legal expenses/settlements; (d) amortization of pension and postretirement actuarial losses/gains; (e) net plant incident costs/credits; and (f) restructuring, impairment, and plant closing and transition costs/credits.